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Abstract
Background—The association of central arterial stiffness and pressure pulsatility with mild 
cognitive impairment and dementia is not well characterized in the population-based setting.
Objective—The aim of this study was to quantify the cross-sectional association of arterial 
stiffness and pressure pulsatility with mild cognitive impairment and dementia among 4,461 older 
white and black adults from the population-based Atherosclerosis Risk in Communities Study-
Neurocognitive Study.
Methods—We used race-stratified multinomial logistic regression to evaluate associations of 
percentile cut points of carotid-femoral pulse wave velocity, central systolic blood pressure, central 
pulse pressure, and pulse pressure amplification with mild cognitive impairment and dementia 
versus no cognitive impairment.
Results—Among whites, those with carotid-femoral pulse wave velocity or central systolic 
blood pressure ≥75th percentile had a higher prevalence of mild cognitive impairment compared to 
participants <75th percentile (conditional odds ratio (OR); 95% confidence interval (CI): 1.27 
(1.02, 1.56) and 1.28 (1.04, 1.57), respectively) and those with central pulse pressure ≥75th 
percentile had a higher prevalence of mild cognitive impairment (OR 1.27 (95% CI: 1.03, 1.58)) 
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and dementia (OR 1.76 (95% CI: 1.06, 2.92) compared to participants <75th percentile. Also 
among whites, those with pulse pressure amplification ≤25th percentile had a higher prevalence of 
dementia compared to participants >25th percentile (OR 1.65; (95% CI: 1.01, 2.70). Weaker 
associations were seen among black participants.
Conclusion—Higher arterial stiffness and pulsatility were associated with mild cognitive 
impairment and dementia in white participants. Longitudinal characterization of the observed 
associations is warranted to assess whether arterial stiffness and pressure pulsatility predict mild 
cognitive impairment and dementia among older adults.
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Introduction
Elevated central arterial stiffness and pressure pulsatility are emerging risk factors for 
cerebral small vessel disease, mild cognitive impairment (MCI), and Alzheimer’s disease 
(AD)-related dementias [1–5]. As a consequence of central arterial stiffening, the cerebral 
vasculature is subjected to increased pressure and pulsatility [6], leading to cerebral 
hypoperfusion and microvascular ischemia. Chronic cerebral hypoperfusion and repeat 
occurrences of microvascular ischemia may lead to tissue damage [7, 8] manifested in the 
brain as white matter hyperintensities, focal brain infarcts, and brain atrophy [9] that are 
associated with cognitive decline and dementia [10–13]. Studies of the association of arterial 
stiffness and pressure pulsatility with MCI and dementia are few and their results are 
inconsistent [1, 5, 14–18]. Prior studies used various methods to quantify central artery 
stiffness and were limited in the number of cases identified as MCI and AD dementia. 
Differences in these associations by race are also relatively unexplored, despite indications 
that blacks in the United States have an adverse risk profile including hypertension and 
diabetes with unfavorable implications for cerebral microvascular damage, cognitive decline, 
and dementia. Limited data suggest that blacks in the United States might have a high risk of 
dementia and AD dementia compared with whites [19–22].
The burden of MCI and dementia is a salient and growing public health concern as 
populations age [23, 24]. This study examined the cross-sectional associations of central 
arterial stiffness and pressure pulsatility with MCI and dementia among older black and 
white adults in a population-based study. Understanding these associations and their impact 
in diverse populations may offer insights for reductions in the population burden of MCI and 
dementia.
Materials and Methods
Study population
The Atherosclerosis Risk in Communities-Neurocognitive (ARIC) study is a population-
based, longitudinal study of 15,792 participants aged 45–64 years at the time of their 
enrollment in 1987–1989 from the following four US communities: Forsyth County, North 
Carolina; Jackson, Mississippi; Minneapolis, Minnesota; and Washington County, Maryland. 
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Details of the baseline visit have been previously described [25]. This investigation included 
6,538 participants aged 70–89 who attended the visit 5 examination between 2011 and 2013. 
Participants provided written informed consent and the ARIC-NCS study was approved by 
the Institutional Review Boards at all field centers and other study agencies.
We excluded participants with missing information on PWV (n=863), body mass index 
(BMI) ≥40 kg/m2 (n=204) or missing BMI (n=14), major arrhythmias (Minnesota code 
8-1-3, 8-3-1, and 8-3-2; n=190), Minnesota code 8-1-2 with low quality PWV waveforms 
(n=30), aortic aneurysms/abdominal aorta diameter ≥5 cm by ultrasound (n=5), self-reported 
history of aortic or peripheral revascularization or aortic graft (n=94), echocardiographic 
evidence of aortic stenosis (n=28), moderate or greater aortic regurgitation (n=25), and 
missing covariates of interest (systolic blood pressure, heart rate, APOE e4 carriage, 
education, smoking, and physical activity, n=557), and missing determination of cognitive 
status (no cognitive impairment, MCI, or dementia, n=27) [26]. Participants who self-
identified as Asian from any site (n=15), whites from Jackson (n=2), and blacks from 
Minnesota and Maryland sites (n=23) were also excluded due to small numbers. The final 
analytic set included 4,461 participants after the exclusions (see supplemental table S2 for 
comparison of those included and excluded from this analysis).
At visit 5 participants were asked to bring all prescription and nonprescription medications 
taken within the prior two weeks, to not consume food or drinks, and refrain from tobacco 
and vigorous physical activity after midnight prior to the clinic visit or for 8 hours prior to 
the visit. Participants underwent a blood draw, B-mode scan of the abdominal aorta, standard 
12-lead electrocardiogram (ECG), anthropometric measurements, extensive 
neuropsychometric testing, cerebral magnetic resonance imaging (MRI) on a subset of 
participants, assessment of functional abilities, and interviewer-administered questionnaires 
to obtain medical history and lifestyle information. Body weight was measured to the 
nearest 0.1 kilogram and height was recorded to the nearest centimeter. Three seated blood 
pressure measurements were obtained after a five-minute rest using an oscillometric 
automated sphygmomanometer (Omron HEM-907 XL, Omron Co. Ltd., Kyoto, Japan) and 
the average of the last two measurements was used.
Hypertension was defined as SBP ≥140 mm/Hg, diastolic blood pressure (DBP) ≥90 
mm/Hg, or anti-hypertensive medication use. Diabetes was defined as fasting glucose ≥126 
mg/dL, non-fasting glucose ≥200 mg/dL, anti-diabetic medication use, or self-reported 
physician diagnosis of diabetes. Prevalent coronary heart disease (CHD) and stroke were 
defined by baseline status and ARIC cohort surveillance data through the data of the 
participant’s visit 5 examination. Standard resting 12-lead ECGs were digitally acquired 
using a GE MAC 1200 electrocardiograph (GE, Milwaukee, WI) at 10 mm/mV calibration 
and a speed of 25 mm/s. ECGs were centrally processed using GE 12-SL Marquette Version 
2001 (GE, Milwaukee, Wisconsin) at the Epidemiological Cardiology Research Center at 
the Wake Forest School of Medicine. Physical activity was assessed using the Baecke 
questionnaire [27]. Participants self-reported up to four sport activities and the frequency 
(hours/week) and duration (months/year) with which the activity was performed within the 
last year. Each sport activity was assigned a metabolic equivalent [28] thereby allowing for 
the estimation of Metabolic Equivalent of Task (MET)-min/week of activity performed. The 
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MET-min/week was then summed across the four reported activities. Participants that self-
reported not engaging in a sport activity were assigned a MET-min/week value of 0. 
Physical activity was then categorized into tertiles of MET-min/week yielding the following 
groups: 0, tertile 1 ≤676.49, tertile 2 >676.49 & ≤1311.09, tertile 3 >1311.09 of the total 
MET-min/wk.
Pulse wave velocity
Details of the PWV methodology for ARIC-NCS have been reported [29]. Briefly, 
technicians measured PWV using the automated waveform analyzer VP-1000 Plus (Omron 
Co., Ltd., Kyoto, Japan) [30] after participants were supine for 5 to 10 minutes. Carotid and 
femoral arterial pressure waveforms were acquired by applanation tonometry sensors on the 
left common carotid artery and left common femoral artery. Bilateral brachial and posterior-
tibial arterial pressure waveforms were detected by plethysmographic and an oscillometric 
pressure sensor wrapped on both arms and ankles.
PWV was calculated as distance divided by transit time. Distance for carotid femoral PWV 
(cfPWV) was measured with a segmometer (Rosscraft, Surray, Canada) and calculated as 
the carotid to femoral distance minus the distance between the suprasternal notch to carotid. 
Measures of blood pressure were calculated simultaneously on all limbs by the VP-1000 
Plus to obtain measures of estimated central systolic blood pressure (cSBP), central pulse 
pressure (cPP; [cSBP – right brachial DBP]), and pulse pressure amplification (PA; [(right 
brachial SBP- right brachial DBP) / cPP]. Technicians obtain at least two measurements and 
results were averaged. Outliers, defined as values three standard deviations above or below 
the mean, were winsorized for the analyses. Higher values of cfPWV, cSBP, and cPP 
indicate arterial stiffness and pressure pulsatility, whereas lower PA indicates greater 
pressure pulsatility. Repeat visits were conducted for a subset of participants at each field 
center approximately 4–8 weeks later (n = 79; mean age 75.7 years; 46 females). The intra-
class correlation coefficients and 95% confidence intervals (95% CIs) for single 
measurements were 0.70 (0.59, 0.81) for cfPWV [31], 0.58 (0.45, 0.71) for cSBP, 0.60 (0.48, 
0.72) for cPP, and 0.25 (0.09, 0.41) for PA.
Diagnosis of MCI and dementia
The current analyses were limited to ARIC-NCS participants who were seen in person [26]. 
MCI and dementia were ascertained based on the National Institute on Aging-Alzheimer’s 
Association criteria [32, 33] and the Diagnostic and Statistical Manual of Mental Disorders 
(DSM) 5th edition [34]. Details of the classification of MCI and dementia have been 
described [26]. Briefly, the criteria incorporated neuropsychometric information (e.g. change 
in digit symbol substitution test (DSST), delayed word recall task (DWRT), and word 
fluency test (WFT) scores from previous visits 2, 3, and 4 and the current visit 5); the Mini-
Mental State Examination Test (MMSE) score; the clinical dementia rating score (CDR) 
[35]; and the functional activities questionnaire (FAQ; Figure 1) [36]. The ARIC-NCS 
Classification Committee reviewed participants with suspected MCI or dementia and a 
diagnosis was confirmed by one physician and one neuropsychologist with adjudication by a 
third reviewer if applicable. MCI and dementia were considered as mutually exclusive where 
those with dementia were not considered to have MCI. Etiologic diagnoses were assigned 
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for participants who were seen in person and classified as having MCI or dementia, as 
previously described [26]. A panel of physicians and neuropsychologists assigned one 
primary etiologic diagnosis and could specify secondary etiologies. In this analysis, we 
evaluated only those with a primary etiology AD or cerebrovascular disease (CeVD). AD 
was defined following the criteria from the National Institute on Aging-Alzheimer’s 
Association working groups [33] and CeVD was operationally defined. Specifically, a 
diagnosis of CeVD was considered primary or secondary according to an algorithm based on 
the core criteria from the National Institute of Neurological Disorders and Stroke-
Association Internationale pour la Recherche et l’Enseignement en Neurosciences criteria 
[37]. The core criteria included neurological examination findings consistent with a 
cerebrovascular origin, a history of stroke, a history of sudden worsening of cognitive 
function in conjunction with a clinically diagnosed stroke, or imaging evidence of either 
extensive white matter hyperintensity burden or infarcts.
Statistical analysis
Participant characteristics by race and cognitive status were estimated as means and standard 
deviations or frequencies and percent, where appropriate. We calculated means and the 95% 
confidence intervals (CI) for cfPWV and pressure pulsatility measures by race and cognitive 
status and adjusted for age, sex, and education.
Multivariable, multinomial logistic regression was used to evaluate associations of 75th 
percentile cut points for cfPWV, cSBP, and cPP and a 25th percentile cut point for PA with 
MCI, dementia, versus no cognitive impairment (referent) and conditional odds ratios are 
reported. The upper 75th percentile cut points were ≥1,324.0 cm/s for cfPWV, ≥157.0 mmHg 
for cSBP, and ≥82.4 mmHg for cPP. The lower 25th percentile cut point was ≤0.853 for PA. 
Analyses were stratified by race and adjusted for age, sex, heart rate, education, study center 
(for whites only due to small numbers in blacks), APOE genotype, smoking status, and 
physical activity. As a priori hypotheses, we also tested interactions by race, hypertension, 
and diabetes. Analyses were stratified by race because of a statistically significant race 
interaction (P<0.1). P-values were two-sided with statistical significance of P<0.05 (SAS, 
version 9.2, SAS Institute, Inc., Cary, NC).
Results
Participant characteristics
Among the ARIC-NCS participants seen in person, 703 (19.8%) white participants were 
identified with MCI and 98 (2.8%) with dementia, and 178 (19.5%) black participants were 
identified with MCI and 39 (4.3%) with dementia. The mean age ranged from 74.0 ± 4.7 to 
79.4 ± 4.5 years, and mean BMI ranged from 26.4 ± 4.8 to 29.4 ± 4.8 kg/m2 across race-
cognitive status groups (Table 1). Among whites and blacks, those with MCI or dementia 
were older, had higher SBP, arterial stiffness and pressure pulsatility, had a lower education, 
and were more likely to have diabetes, prevalent CHD, and prevalent stroke compared to 
those with no cognitive impairment (Table 1).
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Relationships between cfPWV and pressure pulsatility with cognitive status
The age, sex, and education-adjusted, estimated means of cfPWV and pressure pulsatility by 
cognitive status and race are shown in the supplemental table S2. Among whites, after 
adjusting for heart rate, age, sex, education, center, APOE genotype, smoking status and 
physical activity, those with cfPWV or cSBP ≥75th percentile had a higher prevalence of 
MCI compared to participants <75th percentile (odds ratio (OR); 95% CI: 1.27 (1.02,1.56) 
for cfPWV and 1.28 (1.04, 1.57) for cSBP) and those with cPP ≥75th percentile had a higher 
prevalence of MCI and dementia compared to participants <75th percentile (OR:1.27 (1.03, 
1.58) for MCI and OR: 1.76 (1.06, 2.92) for dementia; Table 2). Also among whites, those 
with PA ≤25th percentile had a higher prevalence of dementia compared to participants >25th 
percentile (OR: 1.65 (1.01, 2.70)). Associations of cfPWV, cSBP, cPP and PA with MCI and 
dementia were not statistically significant and estimates had a large variance among black 
participants. There was no evidence for effect modification by hypertension or diabetes, and 
all results were robust to additional adjustment for hypertension or diabetes. Adjustment for 
mean arterial pressure slightly increased the variance of the estimates, but did not visibly 
change the magnitude of the association between cfPWV and MCI or dementia. We thus 
present the main results unadjusted for mean arterial pressure
Association of cfPWV and pressure pulsatility with the primary etiology of MCI and 
dementia
AD was more frequent than CeVD as the primary etiology of MCI and dementia among 
whites and blacks (Table 3). Among whites with MCI and among blacks with dementia, 
those with CeVD as the primary etiology had higher cfPWV compared to AD as the primary 
etiology. Among whites, those with AD as the primary etiology had consistently higher 
cSBP, cPP and lower PA compared to those with CeVD as the primary etiology among MCI 
and dementia, although the differences were not statistically significant. Conversely, among 
blacks, those with CeVD as the primary etiology had consistently higher cfPWV, cSBP, and 
cPP compared to those with AD as the primary etiology among MCI and dementia, although 
the differences were not statistically significant.
Discussion
We evaluated the association between central arterial stiffness and pressure pulsatility with 
the prevalence of MCI and dementia in a cohort of white and black older adults in the United 
States. Our results show that higher central arterial stiffness and pressure pulsatility were 
associated with the prevalence of MCI and dementia in whites. We also showed that the 
association between cfPWV and pressure pulsatility with the prevalence of MCI and 
dementia varied across central arterial stiffness and pulsatility measures, although, cPP was 
consistently associated with the prevalence of MCI and dementia among whites.
Central arterial stiffness is associated with impaired cognitive function in community-based 
studies [38–42], as well as in systematic reviews and meta-analyses [1–4]. In contrast, 
studies of the association of central arterial stiffness and pressure pulsatility with MCI and 
dementia yielded inconsistent results [1, 14–18]. While most prior studies distinguished 
between CeVD and AD dementia, CeVD and AD dementia diagnoses are almost always 
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clinical and therefore subject to substantial imprecision. Furthermore, the two pathologies 
often overlap and most dementias in the elderly are a mix of both [43].
PWV was reported to be higher among those with CeVD, AD dementia, and MCI of either 
etiology compared to those with normal cognitive function among elderly adults reporting 
memory impairment in an outpatient setting [14]. Similarly, a meta-analysis report showed 
that PWV was higher among those with CeVD compared to those with AD dementia or 
controls [16], although these analyses pooled studies that used heterogeneous methods of 
CeVD and AD dementia diagnostic classification, different PWV methods, as well as studies 
reporting on brachial-ankle PWV (baPWV). The resulting heterogeneity is of concern, not 
least because baPWV reflects both central and peripheral arterial stiffness and may bias 
associations with central arterial stiffness, i.e. the property that is more related to 
cardiovascular disease and end-organ function.
One of the two prospective studies in the literature, the Framingham Offspring study, 
reported cfPWV to be associated with the 10-year incidence of MCI among all study 
participants and with the incidence of all-cause dementia among those without diabetes [5]. 
Further analysis showed that cPP was not associated with the risk of MCI or dementia. The 
other prospective evaluation - the Rotterdam Study - did not detect an association between 
cfPWV and the risk of CeVD or dementia after a mean follow-up of 4.4 years, although the 
number of cases of CeVD was small (11 incident cases of CeVD) and MCI was not 
ascertained [15]. In the current study, estimates between cfPWV and the prevalence of MCI 
among whites were slightly higher than for dementia, but the opposite was seen for cPP, 
suggesting that it may be informative to evaluate multiple measures of arterial stiffness and 
pressure pulsatility.
Our primary analyses did not rely on etiological subtypes of dementia (CeVD versus AD 
dementia), because the majority of our dementia cases have more than one etiologic 
diagnosis [26], and because we recognize that a clinical diagnosis of CeVD has poor 
sensitivity and specificity [44, 45]. In secondary analyses, we evaluated cfPWV and pressure 
pulsatility among those with a primary etiologic diagnosis of CeVD or AD. Our results 
showed that cfPWV was higher for CeVD compared to AD in all subgroups, but statistically 
significant for whites with MCI and blacks with dementia. Pressure pulsatility, however, was 
consistently higher for those with AD diagnosis compared to those with CeVD diagnoses 
among whites, but higher for CeVD compared to AD among blacks. Although cfPWV and 
pressure pulsatility may have stronger associations with CeVD than AD dementia, evidence 
suggests that both individuals with CeVD and AD dementia have higher cfPWV than those 
with MCI and normal cognitive function [14]. Moreover, cfPWV is associated with 
increases in cerebral β-amyloid deposition among older adults [46], suggesting that central 
arterial stiffness could contribute to the accumulation of β-amyloid that is associated with 
AD-related dementias. More precise etiological diagnoses using biomarkers for 
cerebrovascular and Alzheimer disease will be needed to refine relationships between 
cfPWV, pressure pulsatility, and disease mechanisms.
We add to the literature an evaluation of central arterial stiffness and pressure pulsatility 
measures among a large sample of white and black older adults with a detailed and up-to-
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date characterization of MCI and dementia. The evidence relating central arterial stiffness 
and pressure pulsatility to MCI and dementia is based on studies of predominantly white 
individuals. Interestingly, we detected an effect modification by race by which the observed 
associations were stronger among whites. This is in contrast to what we expected, since 
blacks have a high prevalence of risk factors for vascular disease and dementia such as 
hypertension, diabetes, and stroke. The cumulative effects of these risk factors, arterial 
stiffness, and pressure pulsatility over the life course may have larger effects on the 
neurovascular system and cognitive status than PWV measured later in life when the 
association is attenuated. Longitudinal characterization of the observed associations is 
warranted to assess whether arterial stiffness and pressure pulsatility predict MCI and 
dementia among white and black older adults, particularly since the ARIC-NCS study 
documented a higher prevalence of cerebral infarcts at baseline [22] and a greater increase in 
white matter hyperintensities over a median of 10.6 years among black compared with white 
participants [21].
Increased central arterial stiffness and pressure pulsatility have been posited to contribute to 
cerebral microvascular damage, cognitive impairment, and dementia by reducing mean 
cerebral blood flow and increasing pulsatile stress in the brain. Additional pathways 
contributory to cognitive decline and dementia associated with cerebral hypoperfusion have 
been proposed [47, 48]. Individuals with dementia have lower mean cerebral blood flow and 
higher pulsatile flow velocity in middle cerebral arteries, compared to those with normal 
cognition [49]. PWV [50] and cPP [51] are associated with these hemodynamic alterations 
in the middle cerebral artery, and cerebral β-amyloid deposition among older adults [46], as 
further links between PWV and cerebral microvascular damage, cognitive impairment and 
dementia.
Our study has several limitations. The cross-sectional design precludes the assessment of 
temporality (and of causality) in the observed associations. ARIC-NCS visit 5 participants 
that were excluded from these analyses were older, had a higher BMI and MAP, and a higher 
prevalence of hypertension and coronary heart disease compared to participants included in 
the analysis. Thus, the observed associations may have been attenuated since participants 
included in the analysis were healthier than those we excluded. Associations with PA may 
also have been attenuated due to the lower measurement repeatability of PA. The estimated 
ICC for an average of 2 measurements of PA in this study would be 0.45, according the 
Spearman-Brown formula [52]. An ICC of 0.45 is fair according to Fleiss [53], but 
additional replicates would improve the repeatability. Future studies, therefore, should 
evaluate their repeatability estimates and take an average of measures that would optimize 
their ICC. On occasion, some PWV measurements were not collected due to technical 
difficulties, participant factors, and scheduling conflicts. Since black participants in the 
ARIC-NCS cohort predominantly reside in Jackson, MS, the observed associations may not 
generalize to blacks as a diverse demographic group. An additional limitation to consider is 
the potential for survival bias due to attrition over the course of >25 years of follow-up, 
which predominantly affected the black members of the cohort. Differential survival by race 
may have contributed to differences in risk factor profiles and in associations among whites 
and blacks in ARIC-NCS. The surviving cohort members likely are healthier and more 
vigorous than those who did not take part in the examination, which would – in general – 
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tend to attenuate the observed associations. The internal validity of the associations 
estimated in this study is supported by our multivariable statistical adjustment for participant 
characteristics that influenced attrition, and we deem our results from this population-based 
cohort to be generalizable to other populations of older adults of comparable demographic 
characteristics. Although we were able to subdivide our MCI and dementia groups by 
presumed etiology, assignment of a vascular etiology has challenges that may lead to loss of 
sensitivity and specificity, and it further reduced subgroup sizes, especially in blacks.
Central artery stiffening is largely age-related, but also modifiable and may be a possible 
target for intervention intended to prevent and reduce cerebrovascular disease. Arterial de-
stiffening has been observed with blood pressure control [54, 55] and with lifestyle 
interventions such as habitual physical activity [56–59]. In addition to physical exercise, 
weight loss, smoking cessation, salt reduction [59], and dietary interventions [56] have also 
been shown to have promise in reducing central arterial stiffness.
In conclusion, central arterial stiffness and pressure pulsatility are associated with the 
prevalence of MCI and dementia among white older adults. Persuasive epidemiologic 
evidence suggests that central arterial stiffness and pressure pulsatility contribute to 
cerebrovascular disease and dementia. Knowledge of the degree to which central arterial 
stiffness and pressure pulsatility adversely impact brain structure and function is therefore 
relevant to strategies to reduce or reverse central arterial stiffness as potential opportunities 
to influence the development of MCI and dementia.
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Figure 1. 
Classification of MCI and dementia included neuropsychometric information (change in 
digit symbol substitution test (DSST), delayed word recall task (DWRT), and word fluency 
test (WFT) scores from previous visits 2, 3, and 4 and the current visit 5); Mini-Mental State 
Examination Test (MMSE); clinical dementia rating score (CDR); and the functional 
activities questionnaire (FAQ).
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Table 3
Adjusted means (95% confidence limits) of cfPWV and pressure pulsatility by primary etiology of MCI and 
dementia by race
MCI Dementia
Whites AD (n=486) CeVD (n=56) AD (n=62) CeVD (n=20)
 cfPWV, cm/s 1154.5 (1120.3, 1188.7) 1286.8 (1200.3, 1373.2) 1158.7 (1074.0, 1243.4) 1216.7 (1078.7, 1354.6)
 cSBP, mmHg 144.1 (141.8, 146.4) 142.5 (136.6, 148.4) 143.9 (138.1, 149.7) 140.8 (131.5, 150.1)
 cPP, mmHg 73.7 (71.7, 75.7) 70.9 (65.8, 76.0) 74.5 (69.5, 79.5) 72.3 (64.2, 80.4)
 PA 0.92 (0.91, 0.93) 0.94 (0.91, 0.97) 0.89 (0.86, 0.92) 0.91 (0.86, 0.96)
Blacks AD (n=139) CeVD (n=19) AD (n=29) CeVD (n=9)
 cfPWV, cm/s 1244.4 (1183.3, 1305.5) 1381.2 (1224.8, 1537.6) 1291.0 (1156.7, 1425.2) 1668.6 (1433.9, 1903.3)
 cSBP, mmHg 146.1 (142.2, 150.0) 154.7 (144.8, 164.6) 147.2 (138.8, 155.7) 157.8 (142.9, 172.6)
 cPP, mmHg 73.4 (69.6, 77.1) 77.2 (66.9, 87.4) 71.6 (63.3, 80.0) 75.6 (61.2, 90.0)
 PA 0.92 (0.90, 0.94) 0.88 (0.83, 0.93) 0.91 (0.87, 0.95) 0.93 (0.86, 1.01)
Values are means (95% confidence limits) adjusted for age, sex, and education
AD: Alzheimer’s disease; CeVD: cerebrovascular disease; MCI: mild cognitive impairment; cfPWV: carotid femoral pulse wave velocity; cSBP: 
central systolic blood pressure; cPP: central pulse pressure; PA: pulse pressure amplification
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